Dr Quin Wills Appointed as Ochre Bio CEO
Oxford-based Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed Dr Quin Wills as CEO. As Founder of Ochre, and previously CSO, Quin has been driving the company’s innovative approach to late-stage liver disease – developing potential new therapeutics to target disease progression. Quin will now lead the company in […]
Ochre Bio appoints ex-Eli Lilly and AstraZeneca VP as Non-Executive Director
The appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics. Oxford-based Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed Dr. Elaine Sullivan as Senior Independent Non-Executive Director, bringing extensive global pharma and business expertise to the company. Elaine will take a leading role […]
Ochre Bio Appoints New Head of Late State Validation to Lead New York Lab
New York, US, Liver disease biotech company Ochre Bio have appointed Mark Lundquist, PhD, MBA, as Head of Late Stage Validation and site lead for their New York City lab. Dr. Lundquist is an experienced oncology and immuno-oncology R&D leader, having previously held roles as Head of Biology and Pharmacology at Alphina Therapeutics and Senior […]
Ochre Bio Announces Leadership Change
OXFORD, England – Ochre Bio, a pioneer in chronic liver disease medicine development, today announced that Jack O’Meara has stepped down as Chief Executive Officer and member of the Board of Directors. Dr. Eliot Forster, who joined Ochre as Chairperson in 2023, will take on the role of Executive Chairperson in an interim capacity. Eliot […]
GSK enters into a multi-year data licence agreement with Ochre Bio to further investigate the drivers of liver disease
OXFORD, England – 12 June 2024 – Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The partnership will provide GSK with access to Ochre Bio’s computational biology, cellular and perfused human organ platforms to generate proprietary human liver datasets and non-exclusive […]
Ochre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease
Oxford, UK — 22 April 2024 — Ochre Bio, a pioneer in chronic liver disease medicine development, today announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis. Within the partnership, Ochre Bio will utilise […]
Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors
17 May 2023, OXFORD, UK Ochre Bio, an innovator in chronic liver disease medicine development, today announced the appointment of Eliot Forster, Ph.D. as Chairperson of the Board of Directors. With decades of experience in pharmaceutical and biotechnology industries, cofounding and leading several companies Dr. Forster has successfully raised more than $550M in equity financing, […]
Ochre Bio to Participate in Upcoming Global Industry Conferences
9 May 2023, OXFORD UK Ochre Bio, an innovator in chronic liver disease medicine development, has announced its participation in upcoming investor and industry conferences, sharing expert perspectives and insights across liver disease and RNA therapeutics, building and scaling startups, and the future of medicine. BioEquity Europe Location: Dublin, Ireland Date/Time: May 15, 12.50 BST […]
Ochre Bio Strengthens Leadership Team and Board of Directors with Liver Disease Translational Expertise
5 April 2023, OXFORD, UK Ochre Bio, an innovator in chronic liver disease medicine development, is pleased to announce the appointment of David Coughlan, PhD as VP of Translational Development and Chinwe Ukomadu, MD, PhD as an Observer on its Board of Directors. Dr. Coughlan will be responsible for translating the findings from Ochre Bio’s […]
Ochre Bio Announces Participation in Upcoming Conferences
OXFORD, England—October 31, 2022 04:00 AM Eastern Daylight Time—Ochre Bio, an innovator in chronic liver disease drug development, today announced its participation in upcoming investor and industry conferences.
